Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2003 Jul;3(7):540-5.

Rethinking clinical trials for cytostatic drugs.

Author information

  • 1The Lawns, Winterbrook Lane, Wallingford, Oxford OX10 9EF, UK. andy.millar1@virgin.net

Abstract

The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design--survival as an end point and simultaneous combination with cytotoxic chemotherapy--and indicate possible alternatives.

PMID:
12835674
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk